What is Abbott's cash & equivalents?

Abbott (ABT) reported cash & equivalents of $6.8B in Q1 2026.

How has Abbott's cash & equivalents changed year-over-year?

Abbott's cash & equivalents increased by 4.1% year-over-year, from $6.53B to $6.8B.

What is the long-term trend for Abbott's cash & equivalents?

Over 5 years (2020 to 2025), Abbott's cash & equivalents has grown at a 4.5% compound annual growth rate (CAGR), from $6.84B to $8.52B.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Abbott ABT Cash & Equivalents

Cash & Equivalents at other companies

Becton, Dickinson and CompanyBDX

$1.02B+49.0%

Bio-Rad LaboratoriesBIO

$509M-2.7%

Johnson & JohnsonJNJ

$20.42B+9.9%

HaemoneticsHAE

$245.44M-20.0%

ArtivionAORT

$55.76M+47.9%

Merit Medical SystemsMMSI

$488.08M+23.4%

Other financials

Income statement

See full

Revenue$12.6B+13.0%

Gross profit$7.3B+15.6%

Operating income$1.7B-17.5%

Net income$928.0M-47.8%

EPS (diluted)$0.53-47.5%

Balance sheet

See full

Total debt$34.0B+157%

Total equity$52.1B+6.7%

Total assets$110.43B+35.6%

Cash flow

See full

Operating cash flow$1.3B-7.2%

CapEx$399.0M-17.6%

Free cash flow$916.0M-1.8%

Valuation

See full

Market cap$179.51B-18.3%

Enterprise value$206.76B-13.1%

P/E33.1×+17.4×

P/S3.9×-1.2×

Profitability

See full

Gross margin56.6%+0.6pp

Operating margin15.8%-1.7pp

Net margin11.6%-20.8pp

FCF margin16.3%+0.6pp

Returns & leverage

See full

Return on equity12.4%-18.4pp

Debt / equity0.7×+0.4×

Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Abbott's cash & equivalents?: Abbott (ABT) reported cash & equivalents of $6.8B in Q1 2026.
How has Abbott's cash & equivalents changed year-over-year?: Abbott's cash & equivalents increased by 4.1% year-over-year, from $6.53B to $6.8B.
What is the long-term trend for Abbott's cash & equivalents?: Over 5 years (2020 to 2025), Abbott's cash & equivalents has grown at a 4.5% compound annual growth rate (CAGR), from $6.84B to $8.52B.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.